异柠檬酸脱氢酶基因突变与急性髓系白血病的研究进展  

Research Advances of IDH Gene Mutation and AML——Review

作　　者：孙明东[1] 郑永青[1] 

机构地区：[1]滨州医学院附属滨州市人民医院血液科,山东滨州256610

出　　处：《中国实验血液学杂志》2014年第5期1485-1489,共5页Journal of Experimental Hematology

摘　　要：异柠檬酸脱氢酶(IDH)基因突变是一种新的急性髓系白血病(AML)中的突变,其可能参加了白血病的发生。IDH突变在成人AML,尤其是正常核型AML中有较高的发生率,其不同亚型对成人AML预后存在不同的影响,同时受其他分子生物学的的影响。该突变与AML的治疗反应、白血病残留、复发等相关,可以作为AML的一种检验标志,并可作为其MRD的监测手段。IDH突变有可能成为一种新的判断AML预后和指导治疗的指标。本文就IDH基因突变与AML,尤其是与AML临床特征关系的研究进展进行了综述。The isocitrate dehydrogenase （IDH） gene mutation has been recently found, which may be involved in the occurrence of leukemia. The incidence of IDH gene mutation in the patients with adult acute myeloid leukemia（AML） is high, especially in the AML patients with normal karyotype. Different subtype and molecular biology of IDH display a different effect on the AML prognosis. This gene mutation is related with treatment response, residual, recurrence of leu- kemia, and it could be a sign of test and a monitoring tool of minimal residual disease（MRD）. The IDH gene mutation may be an index for predicting prognosis and guiding therapy. In this article, the research progress of IDH gene mutation and its correlation with acute myeloid leukemia, especially with the clinical characteristics, are reviewed.

关 键 词：异柠檬酸脱氢酶 急性髓系白血病 基因突变 

分 类 号：R733.71[医药卫生—肿瘤]